Cellebrite DI Sees Unusually High Options Volume (NASDAQ:CLBT)

Key Points

• Options activity surged: Traders bought 19,988 call options in Cellebrite DI, roughly 3,311% above the typical volume of 586 contracts.
• Shares fell sharply: CLBT dropped 31.2% to $10.48 on unusually heavy trading volume, approaching its one-year low of $9.58.
• Analyst sentiment remains moderately bullish: Five analysts rate the stock a Buy and one rates it Hold, with a consensus price target of $21.80, while insiders have sold 157,810 shares worth about $2.48 million over the past 90 days.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) saw unusually large options trading activity on Thursday. Traders acquired 19,988 call options on the stock. This is an increase of approximately 3,311% compared to the typical volume of 586 call options.

Wall Street Analyst Weigh In

Several brokerages have recently commented on CLBT. DA Davidson increased their target price on Cellebrite DI from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Weiss Ratings raised Cellebrite DI from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, May 18th. Finally, Needham & Company LLC reduced their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Cellebrite DI has an average rating of "Moderate Buy" and a consensus price target of $21.80.

Cellebrite DI Trading Down 31.2%

Shares of NASDAQ:CLBT traded down $4.76 during trading on Thursday, hitting $10.48. 14,342,864 shares of the company's stock were exchanged, compared to its average volume of 1,935,842. The firm has a market cap of $2.62 billion, a P/E ratio of 37.55, a PEG ratio of 1.99 and a beta of 1.18. The firm has a 50-day moving average price of $14.59 and a two-hundred day moving average price of $14.09. Cellebrite DI has a 1-year low of $9.58 and a 1-year high of $19.98.

Insider Transactions at Cellebrite DI

In related news, CEO Thomas E. Hogan sold 103,188 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the sale, the chief executive officer directly owned 590,777 shares in the company, valued at $9,310,645.52. This represents a 14.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CRO Marcus Jewell sold 12,658 shares of the firm's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the sale, the executive directly owned 440,101 shares of the company's stock, valued at $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 157,810 shares of company stock valued at $2,475,185. Corporate insiders own 5.70% of the company's stock.

Institutional Trading of Cellebrite DI

A number of institutional investors have recently bought and sold shares of the business. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its stake in shares of Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company's stock valued at $34,000 after purchasing an additional 850 shares during the period. Advisory Services Network LLC acquired a new stake in shares of Cellebrite DI during the third quarter worth $40,000. CWM LLC increased its holdings in Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company's stock valued at $44,000 after purchasing an additional 889 shares during the last quarter. Elevation Wealth Partners LLC bought a new stake in Cellebrite DI in the second quarter valued at about $44,000. Finally, First Horizon Corp lifted its stake in Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company's stock valued at $52,000 after buying an additional 2,337 shares during the period. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source